Exicure, Inc..
XCUR.US | Research and experimental development on natural sciences and engineering
Exicure, Inc. is a biotechnology company focused on the development of nucleic acid therapies targeting ribonucleic acid (RNA). Their proprietary Spherical Nucleic Acid (SNA) architecture is designed to enhance the delivery of therapeutic oligonucleotides into cells and tissues. The company's pipeli...Show More
Better Health for All
0
Exicure, Inc. is a biotechnology company primarily focused on developing therapeutics for serious diseases such as hematologic diseases (multiple myeloma, sickle cell disease, acute myeloid leukemia), inflammatory disorders, oncology, and genetic diseases.
1
Its core business is dedicated to improving health outcomes, with 100% of its portfolio aimed at delivering revolutionary health benefits. The company has no revenue from products with negative health impacts.
2
As a development-stage company, its products are not yet widely marketed, leading to a neutral score for safety record due to a lack of data on user harm or adverse event rates for commercialized products. For the quarter ended June 30, 2025, Exicure reported $0.9 million in Research and Development (R&D) expenses.
3
The company states it treats data with respect and will not share information with any third party.
4
Exicure has completed a Phase 2 study for GPC-100 in multiple myeloma patients and has ongoing Phase 2 clinical trials for its CXCR4 inhibitor.
5
However, an internal investigation in 2021 revealed that a former employee misreported data from research experiments related to the XCUR-FXN program, impacting public presentations and SEC filings between January 7, 2021, and August 12, 2021.
6
The company's therapeutic approach of dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade is protected by an expanded patent portfolio granted in the United States, Japan, Australia, and Taiwan, with no evidence of flexibility for global health needs.
7
Fair Money & Economic Opportunity
0
Exicure, Inc. is a biotechnology company focused on developing nucleic acid therapies, not a financial institution.
1
The 'Fair Money & Economic Opportunity' value and its associated KPIs are designed to assess companies involved in lending, insuring, moving, or storing money, and their impact on financial inclusion for underserved populations. As Exicure does not offer financial services, consumer credit products, or manage customer financial data, none of the provided articles contain relevant evidence to score the company against the specific quantitative KPIs in this rubric.
2
The company has also reported net losses for the year ended December 31, 2024,
3
and for the nine months ended September 30, 2025,
4
indicating no pre-tax profit available for community finance reinvestment.
Fair Pay & Worker Respect
-50
The company has no collective bargaining agreement, indicating 0% of employees are covered by unions.
1
Employee reviews on Glassdoor show an overall rating of 3.1 out of 5 stars from 22 reviews, with 47% of employees recommending the company to a friend.
2
This translates to an engagement score of approximately 40/100. Specific employee concerns include understaffing, mismanagement, overwork, burnout, unrealistic deadlines, lack of communication, hostile environment, unequal pay, illegal overtime, late/missed payroll, and lack of diversity.
3
The company conducted layoffs of 60% of staff shortly before holidays without warning or retention packages.
4
A former employee complaint is noted in the 2023 annual report, alongside securities class action and shareholder derivative lawsuits.
5
Fair Trade & Ethical Sourcing
0
No evidence available to assess Exicure, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-50
The company restated its first and second quarter unaudited interim condensed consolidated financial statements for 2023 via Form 10-Q/A's, indicating two restatements in that year.
1
It has a formal whistleblower hotline and online submission process, emphasizing confidentiality for reporters, but there is no evidence of independent investigation processes.
2
Additionally, the company has an anti-corruption policy that explicitly addresses FCPA compliance, anti-bribery, and gifts/gratuities, including specific examples of prohibited conduct, but lacks information on training frequency or effectiveness metrics.
3
Kind to Animals
-60
Exicure, Inc. historically conducted preclinical studies using animal models, including rats, mice, and non-human primates, as part of its research and development programs.
1
The company's 2019 10-K mentions that preclinical tests included animal studies and that the Animal Welfare Act covered the treatment of certain animals used in research.
2
As of August 2022, in vivo animal studies were ongoing for its SCN9A preclinical discovery program.
3
The company did not disclose specific animal testing volumes or reduction targets during its operational period, nor was there any mention of a policy to restrict or phase out animal testing beyond basic legal compliance. In September 2022, the company suspended all preclinical activities and halted research and development, with R&D expenses being $0 for the year ended December 31, 2024.
4
No War, No Weapons
-20
The company does not engage in activities directly related to war, weapons manufacturing, or military contracts, and there is no evidence of sales to embargoed regimes.
1
Its core business does not involve defense or arms-related activities, nor does it develop or sell dual-use products with military applications.
2
There is no evidence of lobbying efforts related to arms control.
3
However, the company has no grants or programs to mitigate conflict, indicating 0% of revenue invested in peacebuilding or disarmament. There is also no evidence of codified ethical 'red lines' related to controversial weapons.
4
The company has no exposure to any weapons, and no mineral inputs in its products or services.
5
It also has no applicable technology development for peace tech investment, no conflict zone procurement activity, and no applicable ethical red lines for its business model.
6
Planet-Friendly Business
-20
Exicure, Inc. reported annual carbon emissions of 47.6 metric tons CO2.
1
The company also reported a 12.4% reduction in energy consumption, an 8.7% reduction in water conservation, and a 45% minimization of chemical waste.
2
Its waste management efforts resulted in a 63% diversion rate.
3
No environmental compliance violations were reported.
Respect for Cultures & Communities
0
The provided articles primarily focus on Exicure, Inc.'s financial performance, legal proceedings, stock market activity, corporate governance changes, and business transactions. No information or specific data points related to community engagement, cultural impact assessments, local employment, grievance mechanisms, cultural preservation, or any other metrics pertaining to 'Respect for Cultures & Communities' are present in the evidence.
Safe & Smart Tech
-10
The company has reported no material cybersecurity incidents and no incidents of unauthorized data use.
1
It deploys technical safeguards including firewalls, anti-malware, and authentication/authorization.
2
There is no information available regarding a bug bounty program.
3
However, the company faces challenges with European data protection laws (GDPR), which are mentioned as a risk.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Exicure, Inc. on Zero Waste & Sustainable Products.